The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Novel developments in biomarkers for lung cancer screening
Luis Montuenga, PhD, University of Navarra, Pamplona, Spain, gives an overview of promising biomarkers under investigation for lung cancer screening. Imaging has been touted as a potential biomarker due to advances in radiomics and artificial intelligence. In the field of liquid and blood biomarkers, T-cell receptor (TCR) sequencing is also gaining traction in this area of research. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
